Advertisement

Topics

Latest "Rentschler Fill Solutions GmbH" News Stories

15:23 EST 13th November 2018 | BioPortfolio

Here are the most relevant search results for "Rentschler Fill Solutions GmbH" found in our extensive news archives from over 250 global news sources.

More Information about Rentschler Fill Solutions GmbH on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Rentschler Fill Solutions GmbH for you to read. Along with our medical data and news we also list Rentschler Fill Solutions GmbH Clinical Trials, which are updated daily. BioPortfolio also has a large database of Rentschler Fill Solutions GmbH Companies for you to search.

Showing "Rentschler Fill Solutions GmbH" News Articles 1–25 of 7,600+

Extremely Relevant

CMO Rentschler signs Ultragenyx fill/finish deal for US supply

Ultragenyx Pharmaceutical is transferring fill/finish activities for Mepsevvi from Rentschler Biopharmaâs facility in Germany, to Rentschler Fill Solutions in Austria.


Rentschler Fill Solutions, Ultragenyx in Fill/Finish Pact

Rentschler to provide fill/finish services for the U.S. commercial supply of Mepsevii

Rentschler Fill Solutions und Ultragenyx geben Kollaboration für die Abfüllung des Arzneimittels Mepsevii zur kommerziellen Auslieferung in den USA bekannt

Dow Jones hat von EQS/DGAP eine Zahlung für die Verbreitung dieser Pressemitteilung über sein Netzwerk erhalten. DGAP-Media / 2018-05-30 / 11:00 *Rentschler Fill Solutions und Ultragenyx geben Kol...


Rentschler Fill Solutions and Ultragenyx Start Fill & Finish Collaboration for the US Commercial Supply of Drug Product Mepsevii

- Collaboration provides Ultragenyx access to Rentschler Fill Solutions' new center of excellence for the aseptic filling of biopharmaceuticals. - MepseviiTM, developed in collaboration with Rentschler Biopharma, is the first and only drug approved for the treatment of children and adults with mucopolysaccharidosis VII, a rare genetic disorder. ...

Rentschler Fill Solutions Granted GMP Certificate

For the European market from the Austrian Agency for Health and Food Safety

Rentschler Fill Solutions Makes Key Hire

With over two decades experience, Dr. Margit Klotz joins the company as general manager, Operations

CMO collaborates on production of drug product of Mepsevii

Contract manufacturing organisation (CMO) and aseptic fill and finish services expert, Rentschler Fill Solutions, has announced its collaboration with Ultragenyx Pharmaceutical for the production of the drug product of the injectable Mepsevii

Rentschler Fill Solutions names General Manager Operations

Dr Margit Klotz to oversee Process Development & Manufacturing, Quality and Engineering, effective 1 August 2018

Ultragenyx taps Rentschler for Mepsevii commercial supply

The collaboration will give Ultragenyx access to fill and finish capabilities for its rare disease biologic.

Relevant

Rentschler Biotechnologie: Klaus B. Schoepe

In this episode of PharmaTelevision News Review, Fintan Walton talks to Klaus B. Schoepe, Senior Vice President Client Relations at Rentschler Biotechnologie

Rentschler Biotechnologie GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryRentschler Biotechnologie GmbH Rentschler, a subsidiary of Dr. Rentschler Holding GmbH Co KG is a contract development and manufacturing organization that develops and manufactures biopharmaceuticals. The organization offers bioprocess development, biomanufacturing, and consulting services. Its product include recombinant proteins, such as complex glycoproteins and fusion proteins. Rentsch...

Rentschler Biotechnologie GmbH Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250

SummaryRentschler Biotechnologie GmbH Rentschler, a subsidiary of Dr. Rentschler Holding GmbH Co KG is a contract development and manufacturing organization that develops and manufactures biopharmaceuticals. The organization offers bioprocess development, biomanufacturing, and consulting services. Its product include recombinant proteins, such as complex glycoproteins and fusion proteins. Rentsch...

New financing round at oncgnostics GmbH close

The life sciences company oncgnostics GmbH was able to double its investment of 750,000 euros following the very rapid and successful completion of its second crowd investing campaign on Seedmatch. A group of private investors invests together with beteiligungsmanagement thüringen GmbH (bm|t) in onc...

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligation on a licensee under a patent licence agreement...

Miltenyi Biotec acquires microscopy specialist

Miltenyi Biotec GmbH announced that it has acquired the high-end microscopy specialist LaVision BioTec GmbH. Located in Bielefeld, Germany, LaVision BioTec is a leading global specialist for advanced light-sheet and multiphoton microscopy solutions for life science applications. Since its foundation...

Laufende Fusionskontrollverfahren: Bruker Daltonik GmbH, Bremen (D); Erwerb einer Mehrheitsbeteiligung von 80% an der HAIN LIFESCIENCE GmbH, Nehren (D);

Datum der Anmeldung:28.08.2018Aktenzeichen:B3-128/18Unternehmen:Bruker Daltonik GmbH, Bremen (D); Erwerb einer Mehrheitsbeteiligung von 80% an der HAIN LIFESCIENCE GmbH, Nehren (D);Produktmärkte:in...

Laufende Fusionskontrollverfahren: The Paragon Fund II GmbH & Co. KG, München (D); mittelbarer Erwerb von mindestens 99% der Anteile sowie der Kontrolle über die UCB Innere Medizin GmbH & Co. KG, Monheim (D) und die UCB Primary Care GmbH, Monheim (D);

Datum der Anmeldung:07.08.2018Aktenzeichen:B3-119/18Unternehmen:The Paragon Fund II GmbH & Co. KG, München (D); mittelbarer Erwerb von mindestens 99% der Anteile sowie der Kontrolle über die UCB In...

Strategic Staffing Solutions Names Bob Zhang As Detroit Market Team Leader

"It's truly gratifying to create opportunities for our team and fill roles and needs with current team members.  We hire based on talent rather than Read more...

Original-Research: CO.DON AG (von Sphene Capital GmbH): Buy

Original-Research: CO.DON AG - von Sphene Capital GmbH Einstufung von Sphene Capital GmbH zu CO.DON AG Unternehmen: CO.DON AG ISIN: DE000A1K0227 Anlass der Studie: Update Report Empfehlung: Buy se...

Novasep invests €10m in commercial aseptic fill/finish facility

Novasep is investing â10m ($11.88) in a commercial fill/finish facility for viral vectors, mAbs, and other low-volume biologics, as part of its plan to double in size by 2022.

Fujifilm expands fill/finish services for gene therapies in Texas

Fujifilm Diosynth Biotechnologies has added fill/finish capabilities for late-phase and commercial supply of gene therapies and viral vaccines.

MCI nod to fill additional MBBS seats after completion of admission process puts KNRUHS in a fix

With the Medical Council of India (MCI) giving its nod to fill up 300 additional MBBS seats in some of the private colleges of which 75 seats fall under convenor quota, the management of Kalaoji Narayan Rao University of Health Sciences

Blow-fill-seal Technology Market Worth $386.0 Million by 2023

CHICAGO, September 25, 2018 /PRNewswire/ -- According to the new market research report on the "Blow-fill-seal Technology Market by Material (Polypropylene & Polyethylene), Product (Bottles, Read more...

Overseas doctors must not be used just to fill rota gaps, says leading consultant

Foreign doctors who come to work in the NHS must be treated fairly and should not just be used to fill gaps in hospitals’ rotas, a leading consultant has said.Partha Kar, a consultant endocrinologist...

Nurse practitioners could be poised to fill primary care gap

(Reuters Health) - With the U.S. lurching toward a severe shortage of primary care physicians, nurse practitioners may be poised to fill the void - but only if more can be convinced to live in underserved areas and laws in some states loosen up, a ne...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks